NCT02518698View on ClinicalTrials.gov

Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population

CompletedOBSERVATIONAL

Enrollment

1,163

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions

Prostate Cancer

Interventions

DRUG

Radium-223 dichloride (Xofigo, BAY88-8223)

Therapies used to treat prostate cancer and more specifically castrate resistant prostate cancer inclusively Xofigo (Radium-223 dichloride, BAY88-8223)

Trial Locations (1)

Unknown

Louisville